These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 21779958)

  • 21. Plasma idebenone monitoring in Friedreich's ataxia patients during a long-term follow-up.
    Paredes-Fuentes AJ; Cesar S; Montero R; Latre C; Genovès J; Martorell L; Cuadras D; Colom H; Pineda M; Del Mar O'Callaghan M; Sarquella-Brugada G; Darling A; Artuch R
    Biomed Pharmacother; 2021 Nov; 143():112143. PubMed ID: 34507114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antioxidants and other pharmacological treatments for Friedreich ataxia.
    Kearney M; Orrell RW; Fahey M; Pandolfo M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007791. PubMed ID: 19821439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up.
    Pineda M; Arpa J; Montero R; Aracil A; Domínguez F; Galván M; Mas A; Martorell L; Sierra C; Brandi N; García-Arumí E; Rissech M; Velasco D; Costa JA; Artuch R
    Eur J Paediatr Neurol; 2008 Nov; 12(6):470-5. PubMed ID: 18234531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.
    Di Prospero NA; Sumner CJ; Penzak SR; Ravina B; Fischbeck KH; Taylor JP
    Arch Neurol; 2007 Jun; 64(6):803-8. PubMed ID: 17562928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.
    Rustin P; von Kleist-Retzow JC; Chantrel-Groussard K; Sidi D; Munnich A; Rötig A
    Lancet; 1999 Aug; 354(9177):477-9. PubMed ID: 10465173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermediate-dose idebenone and quality of life in Friedreich ataxia.
    Brandsema JF; Stephens D; Hartley J; Yoon G
    Pediatr Neurol; 2010 May; 42(5):338-42. PubMed ID: 20399388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
    Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
    Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.
    Elincx-Benizri S; Glik A; Merkel D; Arad M; Freimark D; Kozlova E; Cabantchik I; Hassin-Baer S
    J Child Neurol; 2016 Jul; 31(8):1036-40. PubMed ID: 27029487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
    Parkinson MH; Schulz JB; Giunti P
    J Neurochem; 2013 Aug; 126 Suppl 1():125-41. PubMed ID: 23859348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose idebenone treatment in Friedreich's ataxia with and without cardiac hypertrophy.
    Rinaldi C; Tucci T; Maione S; Giunta A; De Michele G; Filla A
    J Neurol; 2009 Sep; 256(9):1434-7. PubMed ID: 19363628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idebenone: an emerging therapy for Friedreich ataxia.
    Meier T; Buyse G
    J Neurol; 2009 Mar; 256 Suppl 1():25-30. PubMed ID: 19283347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review.
    Jain P; Badgujar L; Spoorendonk J; Buesch K
    Ther Adv Rare Dis; 2022; 3():26330040221139872. PubMed ID: 37180421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
    Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of idebenone treatment in patients with Friedreich's ataxia by high-pressure liquid chromatography with electrochemical detection.
    Artuch R; Colomé C; Vilaseca MA; Aracil A; Pineda M
    J Neurosci Methods; 2002 Mar; 115(1):63-6. PubMed ID: 11897364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with high-dose idebenone in Friedreich ataxia.
    Schulz JB; Di Prospero NA; Fischbeck K
    J Neurol; 2009 Mar; 256 Suppl 1(0 1):42-5. PubMed ID: 19283350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and metabolism of idebenone in healthy male subjects.
    Bodmer M; Vankan P; Dreier M; Kutz KW; Drewe J
    Eur J Clin Pharmacol; 2009 May; 65(5):493-501. PubMed ID: 19125241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited.
    Schwabova J; Maly T; Laczo J; Zumrova A; Komarek V; Musova Z; Zahalka F
    J Neurol Sci; 2014 Jun; 341(1-2):64-7. PubMed ID: 24768059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
    Cooper JM; Schapira AH
    Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.
    Zesiewicz T; Heerinckx F; De Jager R; Omidvar O; Kilpatrick M; Shaw J; Shchepinov MS
    Mov Disord; 2018 Jul; 33(6):1000-1005. PubMed ID: 29624723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.